Results 51 to 60 of about 28,065 (271)
ChemSusChem, EarlyView.A sustainable valorization of chestnut wood waste is proposed through microwave‐assisted subcritical water extraction, optimized via central composite design. The extract is fractionated by membrane filtration and resin purification, enabling water recovery (up to 89%) and obtaining a tannin‐rich fraction, used to synthesize a PVA‐based biopolymer ...
Clelia Aimone +9 more
wiley +1 more source
Donepezil Potentiates Nerve Growth Factor-Induced Neurite Outgrowth in PC12 Cells
Journal of Pharmacological Sciences, 2007 Donepezil is a potent and selective acetylcholinesterase inhibitor developed for the treatment of Alzheimer’s disease. To elucidate whether donepezil causes neuronal differentiation, we examined its effect on nerve growth factor (NGF)-induced neurite ...
Toru Oda +5 more
doaj
Neuroprotective effects of donepezil against Aβ25-35-induced neurotoxicity
European Journal of Medical Research, 2022 Purpose The purpose of this study was to investigate the neuroprotective effect of donepezil against β-amyloid25-35 (Aβ25-35)-induced neurotoxicity and the possible mechanism. Methods PC12 cells were conventionally cultured. Serial concentrations of Aβ25-
Bu-Lang Gao +3 more
doaj +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 1119-1131, April 2025.Abstract Large clinical data underscore that heart failure is independently associated to an increased risk of negative cognitive outcome and dementia. Emerging evidence suggests that cerebral hypoperfusion, stemming from reduced cardiac output and vascular pathology, may contribute to the largely overlapping vascular dementia and Alzheimer's disease ...
Mauro Massussi +6 more
wiley +1 more source
QT interval prolongation and Torsades de Pointes with donepezil, rivastigmine and galantamine
Therapeutic Advances in Drug Safety, 2020 Background: Acetylcholinesterase inhibitors (AChEis) including donepezil, galantamine and rivastigmine are used to treat Alzheimer’s disease (AD). This study aimed to evaluate evidence from the case report literature for an association between these ...
Katie Malone, J. Hancox
semanticscholar +1 more source
Food Safety and Health, EarlyView.ABSTRACT This study evaluated the multifunctional ability of Beta vulgaris leaves in dual therapy for Alzheimer's disease (AD) and type 2 diabetes (T2D). Flavonoid‐rich extracts of B. vulgaris leaves (FREBVL) were tested for their antidiabetic properties. The inhibition of α‐amylase and α‐glucosidase was assessed. Anti‐cholinesterase activities against
Gideon Ampoma Gyebi +15 more
wiley +1 more source
Journal of Physiological Sciences, 2020 Oral administration of donepezil, a centrally acting acetylcholinesterase inhibitor, improves the survival of rats with chronic heart failure (CHF). The mechanisms of cardioprotective effects of donepezil, however, remain totally unknown.
Meihua Li +5 more
semanticscholar +1 more source
Progress of non‐motor symptoms in early‐onset Parkinson's disease
Ibrain, EarlyView.This study reviews the research progress related to non‐motor symptoms (NMS) in patients with early onset Parkinson's disease (EOPD), including neuropsychiatric symptoms, autonomic dysfunction, sleep disorders, and sensory disorders and also summarizes the characteristics of NMS in the genetic form of Parkinson's disease (PD).
Fanshi Zhang +5 more
wiley +1 more source
Ibrain, EarlyView.Polysaccharide‐based nanoparticles offer versatile platforms for drug delivery and immune modulation in neurodegenerative diseases. This review highlights their potential in treating Alzheimer's, Parkinson's, and multiple sclerosis, focusing on targeted delivery and neuroinflammation.
Leto‐Aikaterini Tziveleka +5 more
wiley +1 more source
Donepezil ameliorates oxaliplatin-induced peripheral neuropathy via a neuroprotective effect
Journal of Pharmacological Sciences, 2019 Oxaliplatin induces severe peripheral neuropathy. The effect of donepezil, a drug used for treatment of Alzheimer's disease, on oxaliplatin-induced peripheral neuropathy was investigated using both in vivo and in vitro models.
Takehiro Kawashiri +4 more
doaj